$Hims & Hers Health Inc.(HIMS)$ can easily become a $100 billion company in the next decade.
1. $Hims & Hers Health Inc.(HIMS)$ can easily become a $100 billion company in the next decade.
It's revolutionizing the telemedicine market by offering customized drugs for each patient.
Here is everything you need to know about $HIMS, business, investment thesis, financials, everything.
Image
2. Many people get $Hims & Hers Health Inc.(HIMS)$ wrong.
It's not a direct-to-consumer (D2C) generic drug provider.
Its business provides patients with primary care visit for just $39. It then prescribes and fulfills the treatment with an option to personalize the treatment for each patient.
Image
3. $HIMS saw its revenues explode.
Revenues grew at 70% CAGR in the last 5 years, validating the business model.
Its low cost visit+treatment model specifically attracts those who can't afford private healthcare. It exerts a significant competitive pressure on legacy names.
Image
4. Yet, the total addressable market remains huge.
Research firms expects the US telehealth market to reach over $400 billion by 2033.
Even if just 10% of this market could be attributed to direct-to-consumer segment, $Hims & Hers Health Inc.(HIMS)$ has over $40 billion market to expand into.
Image
5. $HIMS free cash flow is exploding.
It's not just growing, it's growing profitably. Its free cash flow already tripled year-over-year and we are yet to end 2024. FCF margin is also doubled from 6.5% to 13%. It's not just growing the top line, it's printing cash.
Image
6. It has a fortress balance sheet. It literally has no debt.
There is only $11 million debt on the balance sheet against $440 million equity. Its annual EBITDA of $60 million can pay all the debt in two months. It has a broad legroom to deploy capital for further growth.
Image
7. Personalized plans constitute a significant competitive advantage.
It has over 1 million subscribers on personalized plans. It's really hard to convince them to leave $Hims & Hers Health Inc.(HIMS)$ for other generic solutions. As it increases portion of personalized plans, its moat also expands.
Image
8. $Hims & Hers Health Inc.(HIMS)$ has significant room for expansion.
It's still not active in sleep, diabetes, fertility and cholesterol. These markets collectively create a $121 billion opportunity. $HIMS will surely enter and expand in these markets.
Image
9. Valuation is still attractive.
It currently has 50% market share in the US D2C telemedicine market. Even if loses some market share and only owns 40% of the market, it'll generate $16 billion revenue. At 20% profit margin, it'll generate $3.2 billion net income. Attach a conservative 30 PE and we have a $100 billion company. It's just beginning.
Image
Source: https://x.com/thexcapitalist/status/1863981194754293913
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
值得关注，生物医药领域我关注的比较多，但是没想到这种商业模式其实更加符合轻资产。值得拥有
Thank you for sharing, I remember since the first time i noticed $Hims & Hers Health Inc.(HIMS)$ on Nov.5th 2024, it has rise over 55%!!!!!
Seems the $Hims & Hers Health Inc.(HIMS)$ are good at making Free cash flow by revenue generated.